Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer

Cancer chemoresistance is regulated by complex genetic and epigenetic networks. In this study, the features of gene expression, methylation, and microRNA (miRNA) expression were investigated with high-throughput sequencing in human breast cancer MCF-7 cells resistant to adriamycin (MCF-7/ADM) and paclitaxel (MCF-7/PTX). We found that: ① both of the chemoresistant cell lines had similar, massive changes in gene expression, methylation, and miRNA expression versus chemosensitive controls. ② Pairwise integration of the data highlighted sets of genes that were regulated by either methylation or miRNAs, and sets of miRNAs whose expression was controlled by DNA methylation in chemoresistant cells. ③ By combining the three sets of high-throughput data, we obtained a list of genes whose expression was regulated by both methylation and miRNAs in chemoresistant cells; ④ Expression of these genes was then validated in clinical breast cancer samples to generate a 17-gene signature that showed good predictive and prognostic power in triple-negative breast cancer patients receiving anthracycline-taxane-based neoadjuvant chemotherapy. In conclusion, our results have generated a new workflow for the integrated analysis of the effects of miRNAs and methylation on gene expression during the development of chemoresistance.

[1]  Jian Jin,et al.  A Methylation-Based Regulatory Network for MicroRNA 320a in Chemoresistant Breast Cancer , 2014, Molecular Pharmacology.

[2]  Balázs Sarkadi,et al.  The role of ABC transporters in drug resistance, metabolism and toxicity. , 2004, Current drug delivery.

[3]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[4]  Robert Brown,et al.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.

[5]  K. Mimori,et al.  Increased CD13 Expression Reduces Reactive Oxygen Species, Promoting Survival of Liver Cancer Stem Cells via an Epithelial–Mesenchymal Transition-like Phenomenon , 2012, Annals of Surgical Oncology.

[6]  Christopher M. Bishop,et al.  Bayesian Regression and Classification , 2003 .

[7]  H. Trompeter,et al.  Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells , 2010, BMC Research Notes.

[8]  Zhenyu Xu,et al.  Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells , 2012, Proceedings of the National Academy of Sciences.

[9]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[10]  Jian Jin,et al.  Methylation‐regulated miR‐149 modulates chemoresistance by targeting GlcNAc N‐deacetylase/N‐sulfotransferase‐1 in human breast cancer , 2014, The FEBS journal.

[11]  V. Denis,et al.  Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells , 2008, Molecular Cancer.

[12]  E. Feierstein,et al.  DNA Methylation of the First Exon Is Tightly Linked to Transcriptional Silencing , 2011, PloS one.

[13]  S. Isakoff,et al.  Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents , 2010, Cancer journal.

[14]  P. Horák,et al.  TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth in vivo , 2014, Scientific Reports.

[15]  Z. Bacso,et al.  Multidrug resistance through the spectacle of P-glycoprotein. , 2009, Current cancer drug targets.

[16]  A. Pintzas,et al.  Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. , 2009, Biochimica et biophysica acta.

[17]  Jian Jin,et al.  MiR‐489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway , 2014, FEBS letters.

[18]  Dario La Sala,et al.  Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug‐resistant tumors: Current views and new therapeutic prospective , 2006, Journal of cellular physiology.

[19]  V. Ling,et al.  Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[21]  S. Ropero,et al.  A microRNA DNA methylation signature for human cancer metastasis , 2008, Proceedings of the National Academy of Sciences.

[22]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[23]  N. Seki,et al.  MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway. , 2013, The Journal of urology.

[24]  H. Dressman,et al.  Genomic signatures to guide the use of chemotherapeutics , 2006, Nature Medicine.

[25]  K. Arai,et al.  Prompt meningeal reconstruction mediated by oxygen-sensitive AKAP12 scaffolding protein after central nervous system injury , 2014, Nature Communications.

[26]  Igor Shats,et al.  Using a stem cell-based signature to guide therapeutic selection in cancer. , 2011, Cancer research.

[27]  L. Esserman,et al.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.

[28]  M. Esteller.  Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[29]  Zhiwei Wang,et al.  Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[30]  Zhimin Zhang,et al.  BTG2: a rising star of tumor suppressors (review). , 2015, International journal of oncology.

[31]  Raghu Kalluri,et al.  The epithelial–mesenchymal transition: new insights in signaling, development, and disease , 2006, The Journal of cell biology.

[32]  V. Castranova,et al.  A population-based gene signature is predictive of breast cancer survival and chemoresponse. , 2010, International journal of oncology.

[33]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[34]  Q. Tao,et al.  Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal Wnt/β-catenin signalling and apoptosis regulation in breast cancer cells , 2013, Journal of cellular and molecular medicine.

[35]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[36]  R. Layfield,et al.  Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. , 2007, International journal of oncology.

[37]  A. Riva,et al.  Docetaxel in the treatment of breast cancer: an update on recent studies. , 2002, Seminars in oncology.

[38]  Gary D. Bader,et al.  GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop , 2010, Bioinform..

[39]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[40]  Jun Miyoshi,et al.  Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation , 2008, Nature Reviews Molecular Cell Biology.

[41]  Robert A. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer (Nature (2007) 449, (682-688)) , 2008 .

[42]  D. Richardson,et al.  The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. , 2006, Carcinogenesis.

[43]  G. Mills,et al.  Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance , 2012, Nature Medicine.

[44]  J. Beijnen,et al.  Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3)* , 2001, The Journal of Biological Chemistry.

[45]  T. Tan,et al.  Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients , 2014, EMBO molecular medicine.

[46]  G. Dontu,et al.  Breast cancer, stem/progenitor cells and the estrogen receptor , 2004, Trends in Endocrinology & Metabolism.

[47]  Peter A. Jones,et al.  Epigenetic Activation of Tumor Suppressor MicroRNAs in Human Cancer Cells , 2006, Cell cycle.

[48]  B. Cady,et al.  The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. , 2003, American journal of surgery.

[49]  G. Del Sal,et al.  Targeting triple negative breast cancer: is p53 the answer? , 2013, Cancer treatment reviews.

[50]  S. Badve,et al.  ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. , 2013, Cancer research.

[51]  L. Pusztai,et al.  Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer , 2013, Clinical Cancer Research.

[52]  M. Nitti,et al.  Role of Glutathione in Cancer Progression and Chemoresistance , 2013, Oxidative medicine and cellular longevity.

[53]  M. Tatari,et al.  EMT as the ultimate survival mechanism of cancer cells. , 2012, Seminars in cancer biology.

[54]  C. Perou,et al.  Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch , 2011, Proceedings of the National Academy of Sciences.